Molecular targeted agents--where we are and where we are going.
10.5732/cjc.013.10051
- Author:
Li YAN
- Publication Type:Editorial
- MeSH:
Angiogenesis Inhibitors;
therapeutic use;
Antineoplastic Agents;
therapeutic use;
China;
Drug Delivery Systems;
Drug Discovery;
Humans;
Immunotherapy;
Molecular Targeted Therapy;
Neoplasms;
therapy
- From:Chinese Journal of Cancer
2013;32(5):225-232
- CountryChina
- Language:English
-
Abstract:
A total of 23 new cancer medicines or indication expansions were approved by the U. S. Food and Drug Administration in 2012. Among these, 12 are new molecular entities (NMEs)--new chemical or biological drugs approved for the first time for oncologic use--and 10 of these NMEs are molecular targeted agents. Among the 10 targeted agents, 4 are anti-angiogenesis agents and 2 are Bcr-Abl pathway inhibitors, targeting well established targets validated by previously approved agents such as bevacizumab (Avastin) or imatinib (Gleevec). Despite this progress, several questions remain: Do these newly approved agents provide sufficient treatment options to manage the broad spectrum of cancers we deal with in the clinic? Where will the next wave of new cancer drugs come from? Where should R&D efforts be invested to continue improve cancer treatment and management, especially for tumor types uniquely prevalent in China? This editorial and the review articles in this special issue of Chinese Journal of Cancer provide an in depth review of the progress and challenges in developing targeted cancer therapies, as well as an outlook of new research areas where near term breakthroughs are expected to overcome some of these challenges.
